

目的: 用大鼠脑对  $\omega$ -conotoxin ( $\omega$ -CTX) 及氨氯地平与 N 型钙通道的内在关系进行分析. 方法: 将大鼠全脑匀浆于 HEPES  $50 \text{ mmol} \cdot \text{L}^{-1}$  (pH 7.4) 缓冲液中, 经  $40\,000 \times g$  离心后, 收集膜区域. 以  $^{125}\text{I}$ - $\omega$ -conotoxin (CTX) 作为放射配体测定. 结果:  $^{125}\text{I}$ - $\omega$ -CTX 与冷冻标本及新鲜标本结合的  $B_{\text{max}}$  无

区别. N 型钙通道的  $K_d$  和  $B_{\text{max}}$  值分为  $0.02 \pm 0.01 \text{ mmol} \cdot \text{L}^{-1}$  和  $1029 \pm 108 \text{ pmol/g}$  蛋白质.  $\omega$ -CTX 及氨氯地平的  $pK_i$  值分别为 9.57 以及  $< 4$ , 普萘洛尔、哌唑嗪、阿托品、组胺的  $pK_i$  值也非常低. 结论: L 型钙离子拮抗剂氨氯地平与 N 离子通道的亲和力很低.

## Enhancement of ( - )-stepholidine on protein phosphorylation of a dopamine- and cAMP-regulated phosphoprotein in denervated striatum of oxidopamine-lesioned rats<sup>1</sup>

GUO Xiang, LIU Jian, ZOU Ling-Long, JIN Jiar<sup>2</sup>, WANG Bo-Cheng<sup>2</sup>, JIN Guo-Zhang<sup>3</sup>

(Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200031, China;

<sup>2</sup>State Key Laboratory of Nuclear Medicine, Wuxi 214063, China)

**KEY WORDS** stepholidine; phosphoproteins; phosphorylation; dopamine D<sub>1</sub> receptors; oxidopamine; corpus striatum; SK&F-38393; Sch-23390

phosphorylation in the denervated striatum of oxidopamine-lesioned rats, but it acts as a D<sub>1</sub> antagonist in normal striatum.

**AIM:** To study effects of ( - )-stepholidine (SPD) on the phosphorylation of a dopamine- and cAMP-regulated phosphoprotein (DARPP-32) in the striatum of oxidopamine-lesioned rats. **METHODS:** The amount of dephospho-DARPP-32 was measured by a back-phosphorylation assay. **RESULTS:** In the striatum of control rats, SPD *per se* had no effect on the phosphorylation of DARPP-32, but it antagonized the decrease by 28 % of dephospho-DARPP-32 induced by the D<sub>1</sub> agonist SK&F-38393. In the denervated striatum of oxidopamine-lesioned rats, SPD decreased the amount of dephospho-DARPP-32 by 44 %. The effect of SPD was completely counteracted by the concomitant administration of the D<sub>1</sub> antagonist Sch-23390. **CONCLUSION:** SPD exhibits D<sub>1</sub> agonistic action on DARPP-32

( - )-Stepholidine (SPD), an alkaloid isolated from Chinese herb *Stephania intermedia* Lo, is a tetrahydroprotoberberine. SPD has high affinities for both dopamine (DA) D<sub>1</sub> and D<sub>2</sub> receptors with a preference for D<sub>1</sub> receptors, and low affinities for non-DA receptors<sup>[1]</sup>. SPD possesses the characteristics of a D<sub>2</sub> antagonist<sup>[2, 3]</sup>.

As for D<sub>1</sub> action of SPD, previous studies reported controversial observations. In rats with 6-d reserpine treatment, SPD reduced D<sub>1</sub> agonist SK&F-38393-induced inhibition of firing activity of nigral DA cells although SPD *per se* had no action, indicating a D<sub>1</sub> antagonistic action<sup>[4]</sup>. In rats with unilateral nigral lesions by oxidopamine, SPD induced a contralateral rotation in the manner similar to SK&F-38393, indicating a D<sub>1</sub> agonistic action<sup>[5]</sup>. SPD bound to high and low affinity sites (R<sub>H</sub> and R<sub>L</sub>) of D<sub>1</sub> receptors and the R<sub>H</sub> could be regulated by GTP, indicating an intrinsic activity to D<sub>1</sub> receptors<sup>[6]</sup>. After blockade of D<sub>2</sub> receptors, SPD stimulated striatal cAMP formation<sup>[7]</sup>. In nigral lesioned rats, SPD induced a firing inhibition of substantia nigra pars reticular

<sup>1</sup> Project supported by the National Natural Science Foundation of China, No 39130091, 39600179; the Foundation of State Key Laboratory of Nuclear Medicine, No 9403; and the Foundation of State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Science, No K016.

<sup>3</sup> Correspondence to Prof JIN Guo-Zhang. Pbn 86-21-6431-1833.

Fax 86-21-6437-0269. E-mail gzjin@server.shnc.ac.cn

Received 1997-04-23

Accepted 1997-11-27

neurons as SK&F-38393 did, but partially reduced SK&F-38393-induced firing inhibition<sup>[8]</sup>. Based on these observations, a D<sub>1</sub> partial agonistic action of SPD is proposed.

There existed a DA- and cAMP-regulated phosphoprotein (DARPP-32, *m* = 32 kDa) in striatal neurons containing D<sub>1</sub> receptors. DA activated adenylyl cyclase (AC) through D<sub>1</sub> receptors. The increased cAMP level stimulated the activity of cAMP-dependent protein kinase (PKA) which phosphorylated DARPP-32. Phospho-DARPP-32 represented a positive feedback signal through which some of the actions of DA might be amplified<sup>[9]</sup>. The pharmacological modulation of DARPP-32 was detected *in vivo*. The phosphorylation state of DARPP-32 was increased by *in vivo* administration of D<sub>1</sub> receptor agonists, and their effects were counteracted by the concomitant administration of D<sub>1</sub> (but not of D<sub>2</sub>) antagonists<sup>[10]</sup>.

To elucidate the action of SPD on D<sub>1</sub> receptors, we evaluated effects of SPD on DARPP-32 phosphorylation in striatum of drug-naïve and oxidopamine-lesioned rats.

## MATERIALS AND METHODS

**Chemicals and reagents** SPD (Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China) was dissolved in H<sub>2</sub>SO<sub>4</sub> 0.1 mmol·L<sup>-1</sup>, then diluted and adjusted to pH 5 with NaOH 0.1 mmol·L<sup>-1</sup>. Apomorphine (Shenyang Pharmaceutical Co, China). SK&F-38393, Sch-23390 and oxidopamine-HCl (RBI, USA). Phenyl methyl sulphonyl fluoride (PMSF), Pepstatin and PKA (Sigma, USA). [ $\gamma$ -<sup>32</sup>P]ATP (185 PBq·mol<sup>-1</sup>, Beijing Yahui Biomedical Co, China).

**Rats and pretreatment** Sprague-Dawley rats ( $\delta$ , 180  $\pm$  s 29 g, Shanghai Experimental Animal Center, Shanghai. Certification No 005 conferred by Animal Management Committee, Chinese Academy of Sciences) were used. Rats were anesthetized with pentobarbital (40 mg·kg<sup>-1</sup>, ip), and injected into unilateral medial forebrain bundle (MFB) with the saline solution (4  $\mu$ L) containing oxidopamine-HCl 9.7  $\mu$ g and ascorbic acid 1  $\mu$ g. After 1 - 4 weeks, lesioned rats were screened in a bowl and the turns in a given time were recorded. Only the rats showing contralateral rotation at a speed of > 5 turns·min<sup>-1</sup> in response to apomorphine (0.2 mg·kg<sup>-1</sup>, ip) and SPD (4 mg·kg<sup>-1</sup>, ip) were used.

**Preparation of the striatal protein extracts** Rats were decapitated 30 min after the intraperitoneal injection of SPD and other DA agents. Striata were dissected and rapidly homogenized in ice-cold Tris-HCl buffer (pH 7.4) 10

mmol·L<sup>-1</sup> containing edetic acid 2 mmol·L<sup>-1</sup>, PMSF 0.1 mmol·L<sup>-1</sup> using ten strokes in a teflon-glass Potter homogenizer.

DARPP-32 was extracted<sup>[11]</sup>. Immediately after homogenization, proteins were precipitated by adding homogenate 200  $\mu$ L to 5 mL of ice-cold zinc acetate 5 mmol·L<sup>-1</sup> and spun at 4000  $\times$  g for 15 min. The pellet was resuspended in citric acid 1 mL (pH 2.8) 10 mmol·L<sup>-1</sup> containing 0.1 % Triton X-100 and pepstatin A 2  $\mu$ g. After centrifugation at 28 000  $\times$  g for 15 min, the supernatant was adjusted to pH 6.5 with Na<sub>2</sub>HPO<sub>4</sub> 0.5 mol·L<sup>-1</sup> and left on ice for 10 min. After centrifugation at 16 000  $\times$  g for 15 min, the final supernatant was kept on ice. Protein concentration was measured<sup>[12]</sup>.

**Back-phosphorylation assay** Phosphorylation was carried out at 30 °C for 60 min in a final volume of 100  $\mu$ L containing HEPES (pH 7.4) 50 mmol·L<sup>-1</sup>, MgCl<sub>2</sub> 10 mmol·L<sup>-1</sup>, egtazic acid 1 mmol·L<sup>-1</sup>, edetic acid 1 mmol·L<sup>-1</sup>, catalytic subunit of PKA 10 mmol·L<sup>-1</sup>, [ $\gamma$ -<sup>32</sup>P]ATP 5 mmol·L<sup>-1</sup>, and striatal proteins 40  $\mu$ g. Phosphorylation was started by the addition of [ $\gamma$ -<sup>32</sup>P]ATP. The reaction was stopped by adding the stopping solution 100  $\mu$ L containing 3 % sodium dodecylsulphate (SDS), 5 % 2-mercaptoethanol, 10 % glycerol, and 0.002 % bromophenol blue in Tris-HCl (pH 6.8) 0.12 mmol·L<sup>-1</sup>.

Samples were boiled for 2 min and then subjected to one-dimensional SDS-polyacrylamide gel electrophoresis (PAGE) using 10 % acrylamide and 0.3 % bis-acrylamide in the resolving gel. Electrophoresis was carried out at 60 V for 15 min, then 120 V until the dye reached the bottom of the gel. Resulting gels were stained with Coomassie blue, destained, and dried. The radioactivity retained on the gel was visualized by phosphorimage analysis (Bio-Rad GS250 Molecular Imaging System, USA). The amount of [ $\gamma$ -<sup>32</sup>P]phosphate incorporated in the 32 kDa protein band was determined using Phosphor Analyst Software. Data were expressed as percentage of incorporation compared to the saline control.

## RESULTS

**DARPP-32 phosphorylation in the striatum of normal rats** SK&F-38393 (3 mg·kg<sup>-1</sup>) lowered [<sup>32</sup>P]phosphate incorporated in the 32 kDa protein band to 72 % of the saline group, showing that the amount of dephospho-DARPP-32 was decreased by 28 %. The simultaneous injection of Sch-23390 (0.01 mg·kg<sup>-1</sup>) antagonized this effect of SK&F-38393. These results were in line with previous reports<sup>[10]</sup>.

After the injection of SPD (4, 10, and 20 mg·kg<sup>-1</sup>), <sup>32</sup>P incorporation was not changed. When

rats were treated with SK&F-38393 and SPD ( $4 \text{ mg} \cdot \text{kg}^{-1}$ ) concomitantly, SPD counteracted the decrease in  $^{32}\text{P}$  incorporation induced by SK&F-38393 (Tab 1). This indicated that the  $\text{D}_1$  action of SPD was similar to the  $\text{D}_1$  antagonist Sch-23390.

**Tab 1. Incorporation of [ $^{32}\text{P}$ ]phosphate in DARPP-32 in the striatum of normal rats and the denervated striatum of oxidopamine-lesioned rats.  $n = 3$  (each was pooled from 2 rats),  $\bar{x} \pm s$ .**

Group	Normal striatum/%	Denervated striatum/%
Saline	100	100
SK&F-38393	$72 \pm 9$	$44 \pm 6$
SK&F-38393 + Sch-23390	$101 \pm 11$	$104 \pm 18$
SPD	$97 \pm 7$	$56 \pm 14$
SK&F-38393 + SPD	$94 \pm 15$	
SPD + Sch-23390		$104 \pm 14$


#### DARPP-32 phosphorylation in the denervated striatum of oxidopamine-lesioned rats

In the denervated striatum, SK&F-38393 ( $3 \text{ mg} \cdot \text{kg}^{-1}$ ) decreased [ $^{32}\text{P}$ ]phosphate incorporated in the 32 kDa band to 44 % of the saline group, and Sch-23390 ( $0.01 \text{ mg} \cdot \text{kg}^{-1}$ ) counteracted the effect of SK&F-38393. The amplitude of  $^{32}\text{P}$  incorporation change induced by SK&F-38393 was much larger than that in normal rats. It suggested the supersensitivity of  $\text{D}_1$  receptors after the oxidopamine lesion.

In the denervated striatum, SPD ( $4 \text{ mg} \cdot \text{kg}^{-1}$ ) decreased [ $^{32}\text{P}$ ]phosphate incorporated in the 32 kDa protein band to 56 % of the saline group. This reduction reflected the decrease of dephospho-DARPP-32 available *in vitro* for the back-phosphorylation and conversely indicated the increase of phospho-DARPP-32 *in vivo*. The simultaneous treatment with Sch-23390 counteracted the effect induced by SPD (Tab 1, Fig 1). These results indicated that after the oxidopamine lesion, the  $\text{D}_1$  action of SPD was similar to the  $\text{D}_1$  agonist SK&F-38393.

#### DISCUSSION

Previous binding assay and AC activity assay have demonstrated that SPD possessed the characteristics of a  $\text{D}_1$  agonist<sup>(7-8)</sup>. The present results found that SPD increased the phosphorylation of DARPP-32 in the



**Fig 1. SDS-PAGE and phosphoimage of back-phosphorylation of proteins in acid extracts. SPD reduced [ $^{32}\text{P}$ ]phosphate incorporated in the 32 kDa protein band of denervated striatum. Lane (a) saline; (b) SPD  $4 \text{ mg} \cdot \text{kg}^{-1}$ .**

denervated striatum of the oxidopamine-lesioned rats. DARPP-32 has been proposed as a molecular marker of dopaminergic cells possessing  $\text{D}_1$  receptors. The phosphorylation of DARPP-32 appears to be specific for a  $\text{D}_1$  agonist. Thus, the present results indicate that SPD acts as a  $\text{D}_1$  agonist in the denervated striatum.

In the intact striatum, however, SPD antagonized the effect of SK&F-38393 on the phosphorylation of DARPP-32 while it *per se* had no effect, indicating a  $\text{D}_1$  antagonist action. This is possibly due to the low intrinsic activity of SPD<sup>(8)</sup> and the existence of endogenous DA. The oxidopamine lesion upregulates the signal transduction mechanisms of  $\text{D}_1$  receptors<sup>[13]</sup>, increases the sensitivity of  $\text{D}_1$  receptor to stimulation. Meanwhile, the endogenous DA is depleted by more than 90 %. Therefore, SPD shows the  $\text{D}_1$  agonist action only after the lesion.

In summary, the agonistic action of SPD on DARPP-32 phosphorylation can be exhibited on supersensitive  $\text{D}_1$  receptors in the denervated striatum, while SPD shows an antagonistic action on normal  $\text{D}_1$  receptors.

## REFERENCES

- Xu SX, Yu LP, Han YR, Chen Y, Jin GZ. Effects of tetrahydroprotoberberines on dopamine receptor subtypes in brain. *Acta Pharmacol Sin* 1989; 10: 104-10.
- Zhang ZD, Jin GZ, Xu SX, Yu LP, Chen Y, Jiang FY, *et al.* Effects of *l*-stepholidine on central nervous and cardiovascular systems. *Acta Pharmacol Sin* 1986; 7: 522-6.
- Zou LL, Chen Y, Song YY, Jin GZ. Effect of (-)-stepholidine on serum prolactin level of female rats. *Acta Pharmacol Sin* 1996; 17: 311-4.
- Sun BC, Jin GZ. Characteristics of (-)-stepholidine on the firing activity of substantia nigral dopamine neurons after repeated reserpine treatment. *Biol Signals* 1992; 1: 331-8.
- Huang KX, Sun BC, Jin GZ. (-)-Stepholidine: a dopamine receptor antagonist shows agonistic effect on rotational behavior in 6-hydroxydopamine-lesioned rats. *Acta Pharmacol Sin* 1992; 13: 17-22.
- Guo X, Wang LM, Liu J, Jin GZ. Characteristics of tetrahydroprotoberberines on dopamine D<sub>1</sub> and D<sub>2</sub> receptors in calf striatum. *Acta Pharmacol Sin* 1997; 18: 225-30.
- Zou LL, Liu J, Jin GZ. Involvement of receptor reserve in D<sub>1</sub> agonistic action of (-)-stepholidine in lesioned rats. *Biochem Pharmacol* 1997; 54: 233-40.
- Sun BC, Zhang XX, Jin GZ. (-)-Stepholidine acts as a D<sub>1</sub> partial agonist on firing activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine-lesioned rats. *Life Sci* 1996; 59: 299-306.
- Hemmings HC Jr, Walaas SI, Ouimet CC, Greengard P. Dopaminergic regulation of protein phosphorylation in the striatum: DARPP-32. *Trends Neurosci* 1987; 10: 377-83.
- Luca MD, Cimino M, Abbracchio MP, Cattabeni F. *In vivo* modulation of striatal phosphoproteins by dopaminergic agents. *Eur J Pharmacol* 1989; 172: 321-8.
- Walaas SI, Aswad DW, Greengard P. A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. *Nature* 1983; 301: 69-71.
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem* 1951; 193: 265-75.
- Barone P, Morelli M, Popoli M, Ciccarelli G, Campanella G, Di Chiara G. Behavioural sensitization in 6-hydroxydopamine lesioned rats involves the dopamine signal transduction: changes in DARPP-32 phosphorylation. *Neuroscience* 1994; 61: 867-73.

100-103

左旋千金藤立定增强大鼠损毁侧纹状体 DARPP-32 蛋白磷酸化的作用<sup>1</sup>

郭翔, 刘健, 邹灵龙, 金坚<sup>2</sup>, 王博<sup>2</sup>, 金国章<sup>3</sup>

(中国科学院上海药物研究所, 上海 200031, 中国; <sup>2</sup>核医学国家重点实验室, 无锡 214063, 中国) R 285-5

关键词 千金藤立定; 磷蛋白; 磷酸化; 多巴胺 D<sub>1</sub> 受体; 羟多巴胺; 纹状体; SK&F-38393; Sch-23390 侧纹状体

目的: 研究左旋千金藤立定 (SPD) 对羟多巴胺损毁大鼠纹状体中 DARPP-32 蛋白磷酸化程度的影响。方法: 反磷酸化测定脱磷 DARPP-32 的含量。结果: SPD 不改变正常大鼠纹状体中 DARPP-32 磷酸化的程度, 但能拮抗 D<sub>1</sub> 激动剂的作用; 对羟多巴胺损毁大鼠的损毁侧纹状体, SPD 使脱磷 DARPP-32 的含量降低 44%, 给予 D<sub>1</sub> 拮抗剂可以拮抗这一作用。结论: 在损毁侧纹状体, SPD 显示 D<sub>1</sub> 激动剂的作用特性, 增加 DARPP-32 蛋白的磷酸化, 而在正常纹状体, SPD 表现为 D<sub>1</sub> 拮抗剂。

## 9th European Congress of Clinical Microbiology and Infectious Diseases

1999 Mar 21 - 24

Berlin

Info: Ms Irmtraud Haller  
Pneumologie I  
Lungenklinik Heckeshorn  
Zum Heckeshorn 33  
D-14109 Berlin  
GERMANY

Phn 49-30-8002-2222. Fax 49-30-8002-2623.